Segall Bryant & Hamill LLC Invests $2.13 Million in LivaNova PLC (NASDAQ:LIVN)

Segall Bryant & Hamill LLC bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 40,477 shares of the company’s stock, valued at approximately $2,127,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of LivaNova by 3.5% during the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock valued at $102,537,000 after buying an additional 62,480 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in LivaNova during the first quarter valued at approximately $94,000. Lazard Asset Management LLC acquired a new stake in LivaNova in the first quarter valued at approximately $84,000. Price T Rowe Associates Inc. MD grew its holdings in LivaNova by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock worth $1,736,000 after purchasing an additional 1,980 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new position in shares of LivaNova during the first quarter worth $397,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Price Performance

NASDAQ:LIVN opened at $51.32 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a 50 day moving average price of $52.13 and a 200-day moving average price of $52.52. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The firm has a market cap of $2.79 billion, a price-to-earnings ratio of 122.19 and a beta of 1.01.

Analyst Ratings Changes

LIVN has been the topic of several research analyst reports. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on shares of LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price objective on the stock. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Mizuho decreased their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and set a $75.00 price objective on shares of LivaNova in a report on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, LivaNova has a consensus rating of “Buy” and an average target price of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.